Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam

Ítems similars

• Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
  per: Giancola, Stephanie E, et al.
  Publicat: (2016)
• Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy
  per: Escolà-Vergé, Laura, et al.
  Publicat: (2019)
• Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study
  per: Miller, Benjamin, et al.
  Publicat: (2016)
• Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
  per: Goodlet, Kellie J, et al.
  Publicat: (2016)
• Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections
  per: Larson, Kajal B., et al.
  Publicat: (2019)